Influenza Illness Duration and Severity by Vaccine Among Adults Aged 18–64 Years, 2022–2023 Influenza Season, Influenza Cases (n = 48)
| Characteristic . | Standard-Dose IIV . | RIV . | P Value . | ||||
|---|---|---|---|---|---|---|---|
| No. . | Mean . | (SD) . | No. . | Mean . | (SD) . | ||
| Time to return to usual healtha, d | 25 | 10.9 | (2.7) | 20 | 10.5 | (3.3) | .560 |
| Daily symptom scoreb | 25 | 0.7 | (0.3) | 20 | 0.6 | (0.4) | .325 |
| Peak FLU-PRO Plus symptom scorec | 25 | 1.4 | (0.6) | 20 | 1.3 | (0.8) | .449 |
| Days of missed work or schoold | 25 | 1.1 | (1.5) | 17 | 1.2 | (1.5) | .724 |
| Characteristic . | Standard-Dose IIV . | RIV . | P Value . | ||||
|---|---|---|---|---|---|---|---|
| No. . | Mean . | (SD) . | No. . | Mean . | (SD) . | ||
| Time to return to usual healtha, d | 25 | 10.9 | (2.7) | 20 | 10.5 | (3.3) | .560 |
| Daily symptom scoreb | 25 | 0.7 | (0.3) | 20 | 0.6 | (0.4) | .325 |
| Peak FLU-PRO Plus symptom scorec | 25 | 1.4 | (0.6) | 20 | 1.3 | (0.8) | .449 |
| Days of missed work or schoold | 25 | 1.1 | (1.5) | 17 | 1.2 | (1.5) | .724 |
Abbreviations: FLU-PRO Plus, inFLUenza Patient-Reported Outcome Plus; IIV, inactivated influenza vaccine; RIV, recombinant influenza vaccine; SD, standard deviation.
aNumber of days from onset until participant had 2 sequential responses of “yes” to the question “Have you returned to your usual health today?” in the FLU-PRO Plus Global Diary Questions or up to 14 days, whichever occurred first. The FLU-PRO Plus is a patient-reported outcome tool that includes symptoms of respiratory tract infection across 8 body systems that has been previously validated for influenza and coronavirus disease 2019 [18, 19]. Three participants did not fill out any FLU-PRO Plus questionnaires and were excluded from all FLU-PRO Plus outcome analyses. P value was estimated with a Cox proportional hazards regression model.
bFLU-PRO Plus total symptom scores calculated each day of the illness episode. P value was estimated using repeated-measures linear regression.
cThe highest total FLU-PRO Plus symptom score of the illness episode. P value estimated using the t test.
dSix participants did not complete end of illness questionnaires and were excluded from this analysis. P value from t test.
Influenza Illness Duration and Severity by Vaccine Among Adults Aged 18–64 Years, 2022–2023 Influenza Season, Influenza Cases (n = 48)
| Characteristic . | Standard-Dose IIV . | RIV . | P Value . | ||||
|---|---|---|---|---|---|---|---|
| No. . | Mean . | (SD) . | No. . | Mean . | (SD) . | ||
| Time to return to usual healtha, d | 25 | 10.9 | (2.7) | 20 | 10.5 | (3.3) | .560 |
| Daily symptom scoreb | 25 | 0.7 | (0.3) | 20 | 0.6 | (0.4) | .325 |
| Peak FLU-PRO Plus symptom scorec | 25 | 1.4 | (0.6) | 20 | 1.3 | (0.8) | .449 |
| Days of missed work or schoold | 25 | 1.1 | (1.5) | 17 | 1.2 | (1.5) | .724 |
| Characteristic . | Standard-Dose IIV . | RIV . | P Value . | ||||
|---|---|---|---|---|---|---|---|
| No. . | Mean . | (SD) . | No. . | Mean . | (SD) . | ||
| Time to return to usual healtha, d | 25 | 10.9 | (2.7) | 20 | 10.5 | (3.3) | .560 |
| Daily symptom scoreb | 25 | 0.7 | (0.3) | 20 | 0.6 | (0.4) | .325 |
| Peak FLU-PRO Plus symptom scorec | 25 | 1.4 | (0.6) | 20 | 1.3 | (0.8) | .449 |
| Days of missed work or schoold | 25 | 1.1 | (1.5) | 17 | 1.2 | (1.5) | .724 |
Abbreviations: FLU-PRO Plus, inFLUenza Patient-Reported Outcome Plus; IIV, inactivated influenza vaccine; RIV, recombinant influenza vaccine; SD, standard deviation.
aNumber of days from onset until participant had 2 sequential responses of “yes” to the question “Have you returned to your usual health today?” in the FLU-PRO Plus Global Diary Questions or up to 14 days, whichever occurred first. The FLU-PRO Plus is a patient-reported outcome tool that includes symptoms of respiratory tract infection across 8 body systems that has been previously validated for influenza and coronavirus disease 2019 [18, 19]. Three participants did not fill out any FLU-PRO Plus questionnaires and were excluded from all FLU-PRO Plus outcome analyses. P value was estimated with a Cox proportional hazards regression model.
bFLU-PRO Plus total symptom scores calculated each day of the illness episode. P value was estimated using repeated-measures linear regression.
cThe highest total FLU-PRO Plus symptom score of the illness episode. P value estimated using the t test.
dSix participants did not complete end of illness questionnaires and were excluded from this analysis. P value from t test.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
